Edgewise Therapeutics Valuation
| EWTX Stock | USD 25.57 0.49 1.95% |
At this time, the firm appears to be undervalued. Edgewise Therapeutics shows a prevailing Real Value of $30.74 per share. The current price of the firm is $25.57. Our model computes the value of Edgewise Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 99.53 %, current valuation of 1.89 B, and Shares Owned By Insiders of 0.46 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Edgewise Therapeutics' valuation include:
Undervalued
Today
Please note that Edgewise Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Edgewise Therapeutics is based on 3 months time horizon. Increasing Edgewise Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Edgewise Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Edgewise Stock. However, Edgewise Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.57 | Real 30.74 | Target 49.43 | Hype 25.77 | Naive 24.73 |
The intrinsic value of Edgewise Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Edgewise Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Edgewise Therapeutics helps investors to forecast how Edgewise stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Edgewise Therapeutics more accurately as focusing exclusively on Edgewise Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Edgewise Therapeutics' intrinsic value based on its ongoing forecasts of Edgewise Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Edgewise Therapeutics' closest peers.
Edgewise Therapeutics Cash |
|
Edgewise Valuation Trend
Analysing the historical paterns of Edgewise Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Edgewise Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Edgewise Therapeutics Total Value Analysis
Edgewise Therapeutics is currently anticipated to have valuation of 1.89 B with market capitalization of 2.37 B, debt of 5.41 M, and cash on hands of 248.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Edgewise Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.89 B | 2.37 B | 5.41 M | 248.4 M |
Edgewise Therapeutics Asset Utilization
One of the ways to look at asset utilization of Edgewise is to check how much profit was generated for every dollar of assets it reports. Edgewise Therapeutics shows a negative utilization of assets of -0.22 percent, losing $0.002236 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Edgewise Therapeutics shows how discouraging it operates for each dollar spent on its assets.Edgewise Therapeutics Ownership Allocation
The majority of Edgewise Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Edgewise Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Edgewise Therapeutics. Please pay attention to any change in the institutional holdings of Edgewise Therapeutics as this could imply that something significant has changed or is about to change at the company.Edgewise Therapeutics Profitability Analysis
Net Loss for the year was (100.16 M) with profit before overhead, payroll, taxes, and interest of 0.About Edgewise Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Edgewise Therapeutics. We calculate exposure to Edgewise Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Edgewise Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.6 M | -1.5 M |
Edgewise Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 63.7 M |
Edgewise Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Edgewise Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Edgewise we look at many different elements of the entity such as Edgewise's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Edgewise Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Edgewise Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Edgewise Therapeutics' worth.Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.